233 related articles for article (PubMed ID: 36009369)
1. How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review.
Merlano MC; Denaro N; Galizia D; Ruatta F; Occelli M; Minei S; Abbona A; Paccagnella M; Ghidini M; Garrone O
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009369
[TBL] [Abstract][Full Text] [Related]
2. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
3. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.
Bracci L; Schiavoni G; Sistigu A; Belardelli F
Cell Death Differ; 2014 Jan; 21(1):15-25. PubMed ID: 23787994
[TBL] [Abstract][Full Text] [Related]
4. From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment.
Fabian KP; Wolfson B; Hodge JW
Front Oncol; 2021; 11():728018. PubMed ID: 34497771
[TBL] [Abstract][Full Text] [Related]
5. Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.
Johnson TS; Mcgaha T; Munn DH
Adv Exp Med Biol; 2017; 1036():91-104. PubMed ID: 29275467
[TBL] [Abstract][Full Text] [Related]
6. Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed.
Abu Eid R; Razavi GS; Mkrtichyan M; Janik J; Khleif SN
Cancer Immunol Res; 2016 May; 4(5):377-82. PubMed ID: 27196429
[TBL] [Abstract][Full Text] [Related]
7. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer.
Opzoomer JW; Sosnowska D; Anstee JE; Spicer JF; Arnold JN
Front Immunol; 2019; 10():1654. PubMed ID: 31379850
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer.
Tsuchikawa T; Takeuchi S; Nakamura T; Shichinohe T; Hirano S
World J Gastrointest Oncol; 2016 Nov; 8(11):786-792. PubMed ID: 27895816
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy.
Qiu Q; Lin Y; Ma Y; Li X; Liang J; Chen Z; Liu K; Huang Y; Luo H; Huang R; Luo L
Front Immunol; 2020; 11():612202. PubMed ID: 33488618
[TBL] [Abstract][Full Text] [Related]
11. Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients.
Baci D; Cekani E; Imperatori A; Ribatti D; Mortara L
Front Immunol; 2022; 13():914890. PubMed ID: 35874749
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
13. Platinum-Based Nanovectors Engineered with Immuno-Modulating Adjuvant for Inhibiting Tumor growth and Promoting Immunity.
Liu L; Chen Q; Ruan C; Chen X; Zhang Y; He X; Zhang Y; Lu Y; Guo Q; Sun T; Wang H; Jiang C
Theranostics; 2018; 8(11):2974-2987. PubMed ID: 29896297
[TBL] [Abstract][Full Text] [Related]
14. The immune suppressive microenvironment affects efficacy of radio-immunotherapy in brain metastasis.
Niesel K; Schulz M; Anthes J; Alekseeva T; Macas J; Salamero-Boix A; Möckl A; Oberwahrenbrock T; Lolies M; Stein S; Plate KH; Reiss Y; Rödel F; Sevenich L
EMBO Mol Med; 2021 May; 13(5):e13412. PubMed ID: 33755340
[TBL] [Abstract][Full Text] [Related]
15. Cellular immune responses towards regulatory cells.
Larsen SK
Dan Med J; 2016 Jan; 63(1):B5188. PubMed ID: 26726907
[TBL] [Abstract][Full Text] [Related]
16. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.
Li Z; Lai X; Fu S; Ren L; Cai H; Zhang H; Gu Z; Ma X; Luo K
Adv Sci (Weinh); 2022 Aug; 9(22):e2201734. PubMed ID: 35652198
[TBL] [Abstract][Full Text] [Related]
18. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.
Wang S; Zhou X; Zeng Z; Sui M; Chen L; Feng C; Huang C; Yang Q; Ji M; Hou P
J Nanobiotechnology; 2021 Oct; 19(1):302. PubMed ID: 34600560
[TBL] [Abstract][Full Text] [Related]
19. Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy.
Kim MJ; Ha SJ
Front Cell Dev Biol; 2021; 9():767466. PubMed ID: 34901012
[TBL] [Abstract][Full Text] [Related]
20. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
Huang Y; Yuan J; Righi E; Kamoun WS; Ancukiewicz M; Nezivar J; Santosuosso M; Martin JD; Martin MR; Vianello F; Leblanc P; Munn LL; Huang P; Duda DG; Fukumura D; Jain RK; Poznansky MC
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17561-6. PubMed ID: 23045683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
